NCT06992479

Efficacy of HFNC Combined With Sequential NIV in Patients With COPD Complicated With Type II Respiratory Failure

Efficacy of Nasal High-flow Oxygen Therapy Combined With Sequential Non-invasive Ventilation in Patients With Chronic Obstructive Pulmonary Disease Complicated With Type II Respiratory Failure

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Beijing YouAn Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to investigate the efficacy of high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation (NIV) in patients with chronic obstructive pulmonary disease complicated with type II respiratory failure. The main questions it aims to answer are: What is the effect of high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation on arterial blood gas indicators in patients with chronic obstructive pulmonary disease and type II respiratory failure? What is the effect of high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation on pulmonary ventilation function in patients with chronic obstructive pulmonary disease and type II respiratory failure? What is the effect of high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation on vital signs in patients with chronic obstructive pulmonary disease and type II respiratory failure? What is the effect of high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation on the quality of life of patients with chronic obstructive pulmonary disease and type II respiratory failure? What is the effect of high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation on complications in patients with chronic obstructive pulmonary disease and type II respiratory failure? Participants will: Receive NIV through a full mask or nasal mask using any of the existing ventilators in the hospital Receive other standard treatments according to the latest GOLD guidelines The general data of patients, arterial blood gas index, pulmonary ventilation function, vital signs index, quality of life and complications before and after treatment were collected.

Conditions

• Chronic Obstructive Pulmonary Disease (COPD)
• Nasal High Flow Oxygen Therapy
• Noninvasive Ventilation
• Respiratory Failure

Interventions

Type	Name	Description
DEVICE	high-flow nasal cannula oxygen therapy (HFNC) combined with sequential non-invasive ventilation (NIV)	The control group was treated with NIV routine treatment. During non-invasive ventilation, patients in both the intervention group and the conventional group will receive NIV through a full mask or nasal mask using any of the existing ventilators in the hospital. Usually, the ventilator was set to the pressure support ventilation mode, and the inspiratory pressure was adjusted to the maximum tolerance to obtain the ideal body weight of 6 \~ 8mL / kg of exhaled tidal volume, and the PEEP was set at 3 \~ 5cmH2O. FiO2 in both groups was set to maintain 88% -92% peripheral blood oxygen saturation. The study group was treated with nasal high-flow oxygen therapy combined with sequential non-invasive ventilation. Patients will receive high-flow oxygen therapy ventilator during the day and in the morning and evening awake time (manufacturer: Hunan Mingkang Zhongjin Medical Technology Co., Ltd., registration number: Xiangji Zhuzhun 20192080049, model: OH60A) treatment. At night (from 10 p.m. to 6
DEVICE	NIV routine treatment	Usually, the ventilator was set to the pressure support ventilation mode, and the inspiratory pressure was adjusted to the maximum tolerance to obtain the ideal body weight of 6 \~ 8mL / kg of exhaled tidal volume, and the PEEP was set at 3 \~ 5cmH2O. FiO2 in both groups was set to maintain 88% -92% peripheral blood oxygen saturation.

Timeline

• Start date: 2021-01-01
• Primary completion: 2024-01-01
• Completion: 2024-01-31
• First posted: 2025-05-28
• Last updated: 2025-05-28

Locations

1 site across 1 country: China